ClinicalTrials.gg

Program

PRTX007

A development code.

Its studies are mostly in Melanoma, led by Primmune Therapeutics.

Furthest: phase 2, since Apr 20, 20261 company-led study, 1 open or runningNext primary completion: Dec 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Primmune Therapeutics11 open or runningphase 2since Apr 20, 2026Apr 20, 2026Dec 2027phase 2 · NCT07565285

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Apr 20, 2026First study: phase 2 study in MelanomaFirst studyNCT07565285 · 48 planned · Australia

Ahead

  1. Dec 2027Primary completion: phase 2 study in MelanomaNCT07565285

TargetBeta

TLR7 →read by rule
“Participants will receive oral PRTX007, a Toll-like receptor 7 (TLR7) agonist prodrug, administered in combination with intravenous pembrolizumab prior to surgical resection.”study text, by rule · the study

Other programs on TLR7

ProgramCompanyFurthest phaseStudies
resiquimodruleStaidson (Beijing) Biopharmaceuticalsphase 314
enpatoranruleMerck KGaA, Darmstadt, Germanyphase 312
afimetoranruleBristol-Myers Squibbphase 312
TLR7 Agonist JNJ-64794964Sino Biopharmaceuticalphase 26
Cholesteryl Pullulan Nanoparticle-formulated TLR7/8 Agonist UI-102ruleunited-immunity-co-ltdphase 21

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07565285Melanoma · Australia2RecruitingDec 202748

How it is read

Names in the registry

  • “PRTX007”, 1 entry

Codes read as this program: PRTX007.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.